Prioritising CVD prevention therapy: Absolute risk versus individual risk factors

Australian Family Physician

Volumn 41, Issue 10, 2012, Pages 805-809

  Doust, Jenny ^a   Sanders, Sharon ^a   Glasziou, Paul ^a   Shaw, Jonathan ^b  

^a BOND UNIVERSITY   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Cardiovascular diseases prevention and control; Risk factors management

Indexed keywords

ANTILIPEMIC AGENT; LIPID;

ADULT; AGED; ARTICLE; AUSTRALIA; BLOOD; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; FEMALE; FOLLOW UP; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; MORBIDITY; MULTICENTER STUDY; RISK ASSESSMENT; RISK FACTOR;

ADULT; AGED; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOLIPIDEMIC AGENTS; LIPIDS; MALE; MIDDLE AGED; MORBIDITY; QUEENSLAND; RISK ASSESSMENT; RISK FACTORS;

EID: 84867667426     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Hunink MGM, Goldman L, Tosteson ANA, et al. The recent decline in mortality from coronary heart disease, 1980-1990; the effect of secular trends in risk factors and treatment. JAMA 1997;277:535-42.
2. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665.
3. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials. Lancet 2010;376:1670-81.
4. Jackson R, Lawes CM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet 2005;365:434-41.
5. Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007;11:1-160.
6. National Vascular Disease Prevention Alliance. Guidelines for the assessment of absolute cardiovascular disease risk. National Heart Foundation,2009 Available at www.heartfoundation.org.au/ SiteCollectionDocuments/guidelines-Absolute-risk. pdf [Accessed 4 June 2012].
7. Heeley EL, Peiris DP, Patel AA, et al. Cardiovascular risk perception and evidence - practice gaps in Australian general practice (the AusHEART study). Med J Aust 2010;192:254-9.
8. Chen L, Rogers SL, Colagiuri S, et al. How do the Australian guidelines for lipid-lowering drugs perform in practice? Cardiovascular disease risk in the AusDiab Study, 1999-2000. Med J Aust 2008;189:319-22.
9. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991;121(1 Pt 2):293-8.
10. Zomer E, Owen A, Magliano DJ, Liew D, Reid C. Validation of two Framingham cardiovascular risk prediction algorithms in an Australian population: the 'old' versus the 'new' Framingham equation. Eur J Cardiovasc Prev Rehabil 2011:18;15-20.
11. Heart Foundation of Australia. Guide to management of hypertension 2008. Updated December 2010. Available at www.heartfoundation. org.au/SiteCollectionDocuments/ HypertensionGuidelines2008to2010Update.pdf [Accessed 4 June 2012].
12. Tonkin A, Barter P, Best J, et al. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: position statement on lipid management - 2005. Heart Lung Circ 2005;14:275-91.
13. Dunstan DW, Zimmet PZ, Welborn TA, et al. The Australian diabetes, obesity and lifestyle study (AusDiab) - methods and response rates. Diabetes Res Clin Pract 2002;57:119-29.
14. National Vascular Disease Prevention Alliance. Guidelines for the management of absolute cardiovascular disease risk. National Stroke Foundation,2012 Available at www.kidney.org.au/LinkClick.asp x?fileticket=A%2BRjUoFXdMg%3D&tabid=635& mid=1584 [Accessed 4 June 2012].
15. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41.
16. Patel A, MacMahon S, Chalmers J, et al on behalf of the ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829- 40.
17. Data and Modelling Section, Pharmaceutical Policy and Analysis Branch, Department of Health and Ageing. Expenditure and prescriptions twelve months to 30 June 2010. Available at www. health.gov.au/internet/main/publishing.nsf/Content/4A3477B8447EC695CA25788600037450/$ File/Expenditure%20and%20prescriptions%20 12%20months%20to%2030%20June%202010.pdf [Accessed 4 June 2012].
18. D'Agostino RB, Vasan RS, Pencino MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117;743-53.
19. Liew SM, Doust J, Glasziou P. Cardiovascular risk scores do not account for the effect of treatment: a review. Heart 2010;97:689-97.